

Press Release

Eurocor's DIOR® DEB shows remarkable performance in diabetics with coronary lesions

First data at 9 months of the DEAR Registry presented at EuroPCR

[Note: Clinical abbreviations expanded at the end of the press release]

Bonn, Germany | Bengaluru, India | May 31, 2011

[Eurocor GmbH](#), a wholly-owned subsidiary of [Opto Circuits \(India\) Ltd.](#), and a leading developer and marketer of interventional products presented the first nine months' data from the Argentinean Registry of the DIOR® balloon in diabetic patients, called DEAR Registry, at one of the leading cardiovascular congresses worldwide, EuroPCR in Paris. The aim of the registry is to assess major clinical events when a paclitaxel-eluting balloon (DIOR®) and a stent are used to treat coronary lesions in a diabetic population. The outcome in this challenging group of patients is a very low single digit TLR rate of 6.6 per cent. The data was presented by Dr. Alfredo E. Rodriguez, MD, PhD [Cardiovascular Research Centre (CECI), Head of Cardiology Department at Otamendi Hospital, Argentina] at a symposium that was dedicated to current experiences with drug-eluting balloons (DEB), arranged by Eurocor.

The primary clinical endpoint to be evaluated for the success of the registry was MACCE at nine months, one year and two years follow up. Patients between the ages of 18 to 85 years, suffering from diabetes mellitus I and II, with a positive stress test, with stable or unstable angina including non-STEMI and those who were eligible for PCI with stent implantations were included. The enrollment started in April 2009 in 3 Argentinean centers. 91 patients complying with the inclusion and exclusion criteria were enrolled in the DEAR Registry. Of these, 74.7 per cent patients suffered from multiple vessel disease.

Dr. Rodriguez also compared the outcomes of the DEAR Registry with the outcomes from other CECI trials that used BMS (on 92 diabetics) and DES (on 129 diabetics). The data shows that the use of DIOR® is effective in the treatment of de novo lesions in diabetics leading to significantly lower rates of TVF and MACCE in comparison to the use of BMS. The outcome at nine months showed a TVF rate of 30.4 per cent for BMS, 18.8 per cent for DES and only 11 per cent for DIOR®, which is remarkable. On the point of MACCE, the outcome shows 32.6 per cent for BMS, 18.6 per cent for DES and only 13.2 per cent for DIOR® DEB.

Dr. Rodriguez commented: "Diabetics with coronary lesions make for a high-risk group of patients. The use of DIOR® DEB to treat these patients, at midterm outcome, seems to be safe as it delivers low incidence of TVF and MACCE. DIOR® DEB could be the right alternative treatment for these patients."

Dr. Rembert Pogge von Strandmann, Clinical Director, Eurocor GmbH commented: "The results of the DEAR study confirm that the DIOR® DEB is a recommended treatment option for high risk patients that suffer from diabetes. We are glad to see ever more positive outcomes from various trials and registries for our DIOR® DEB."

The EuroPCR (12, 567 attendees in 2011) contributes to the promotion of education and information on existing and developing techniques in interventional cardiology. The objective of this annual course is to inform physicians of the latest technological developments and offer practical tips that help interventional cardiologists and cardiac surgeons make the right ethical choice for each individual patient.

Eurocor GmbH: Rheinwerkallee 2, D-53227, Bonn | +49 - 228 / 20 150 - 0

Opto Circuits (India) Ltd.: # 83, Electronics City, Bengaluru 560 100 | +91 80 2852 1040/41/42

Abbreviations

BMS - Bare Metal Stent
DEB - Drug-eluting Balloon
DES - Drug-eluting Stent
MACCE - Major Adverse Cardiac & Cerebrovascular Events
PCI - Percutaneous Coronary Intervention
TLR - Target Lesion Revascularization
TVF - Target Vessel Failure
TVR - Target Vessel Revascularization

About: Eurocor GmbH

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One Heartbeat ahead™ – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is an Opto Circuits (India) Ltd. Company.

For more information, please visit www.eurocor.de and www.optocircuits.com

About: Opto Circuits (India) Limited

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCU

Website: www.optocircuits.com

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Ormed](#), [Mediaid](#) and [Unetixs](#). The company's key markets are North America, Europe and BRIC countries.

Contact

Opto Circuits (India) Ltd.

E: Media - media@optoindia.com;

Investors - ir@optoindia.com

T: +91 80 2852 8088

Adfactors PR

Neha Goenka

E: neha.goenka@adfactorspr.com

T: +91 22 2281 3565